According to the Bangkok Post reported on May 14, marijuana cultivators and business owners have decided to gather for a protest, claiming they have suffered significant losses due to a government policy reversal. However, there are also many voices within the medical community and the marijuana industry that support the government's plans. However, groups advocating for marijuana, such as the "Marijuana Future Alliance," demand that if the government intends to reclassify marijuana as a drug, they must provide scientific evidence to support this decision.
Anutin Charnvirakul, an expert and Minister of Interior, stated that the decision to classify marijuana as a drug must be carefully considered, with scientific research and evaluation as a basis. Anutin Charnvirakul is the leader of the Bhumjaithai party, which has previously advocated for the legalization of marijuana.
Deputy Prime Minister Anudin stated, "This issue will not affect the cooperation between the Party of National Trust and the coalition government," and added, "The issue of cannabis should not be politicized.
Although cannabis has been removed from the list of drugs in Thailand since June 2022 and home cultivation is allowed, concerns have been raised in society about issues such as abuse and addiction among adolescents since legalization. Minister of Health Somjate Sapsutin referenced a study from the Chulabhorn Research Institute's Center for Drug Addiction Research, which found that since the legalization of cannabis in 2022, the rate of cannabis use among young people has increased by 10 times.
Even some marijuana growers are in support of canceling the legalization of marijuana, as their income has significantly decreased since marijuana was legalized due to oversupply. Currently, the price of dried marijuana leaves has greatly dropped. However, Thai Prime Minister Chayut Chan-o-cha has issued instructions to the Ministry of Health to revise the regulations that would reclassify marijuana as a controlled substance within the year. It is expected to prohibit recreational use, but allow for medical use under regulation.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
